[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369818-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369818-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-ultrasound-for-multimodal-cancer-treatment-a-spotlight-on-breast-cancer","Therapeutic Ultrasound for Multimodal Cancer Treatment - A Spotlight on Breast Cancer","","Cancer is a leading cause of mortality worldwide, driving the need for treatment options that improve efficacy, precision, and safety. Focused ultrasound (FUS) is an emerging nonionizing, noninvasive approach with versatile bioeffects being evaluated across preclinical and clinical oncology studies. Its roles include tumor ablation, therapeutic delivery, radiosensitization, sonodynamic therapy, and strengthening tumor-specific immune responses. This review highlights recent advances in breast cancer by linking physical mechanisms with results from studies using FUS alone or with adjunct therapeutics and outlining future directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-ultrasound-for-multimodal-cancer-treatment-a-spotlight-on-breast-cancer/369818/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-ultrasound-for-multimodal-cancer-treatment-a-spotlight-on-breast-cancer/369818.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the core rationale for using focused ultrasound (FUS) in cancer treatment?","Question",{"text":63,"@type":64},"FUS enables nonionizing, noninvasive intervention and can produce multiple bioeffects. These functions support tumor ablation, therapeutic delivery, radiosensitization, sonodynamic therapy, and immune response enhancement.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which breast cancer–related areas does the review focus on?",{"text":68,"@type":64},"The review highlights recent advances in breast cancer care using FUS, summarizing physical principles and reporting outcomes from preclinical and clinical studies. It covers FUS used alone and in combination with adjunct therapeutics for primary and disseminated settings.",{"name":70,"@type":61,"acceptedAnswer":71},"How do breast cancer subtypes influence treatment strategies discussed in the document?",{"text":72,"@type":64},"The document links subtypes to key biomarkers such as ER/PR and HER2, and to clinical variables like grade and proliferation index. It describes differing prognosis and therapeutic targeting needs, including hormone therapy for luminal tumors and HER2-targeted strategies for HER2+ disease, as well as challenges in triple-negative breast cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369818,1791477115,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Annu Rev Biomed Eng. Author manuscript; available in PMC 2025 September 05. |\n| --- | --- |\n\nPublished in final edited form as:  \nAnnu Rev Biomed Eng. 2025 May ; 27(1): 371–402. doi:10.1146/annurev-bioeng-103023-111151 .  \nTherapeutic Ultrasound for Multimodal Cancer Treatment: A Spotlight on Breast Cancer  \nZehra E. F. Demir1 , Natasha D. Sheybani 1,2  \n1 Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA  \n2 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA  \nAbstract  \nCancer remains a leading cause of mortality worldwide, and the demand for improved efficacy, precision, and safety of management options has never been greater. Focused ultrasound (FUS) is a rapidly emerging strategy for nonionizing, noninvasive intervention that holds promise for the multimodal treatment of solid cancers. Owing to its versatile array of bioeffects, this technology is now being evaluated across preclinical and clinical oncology trials for tumor ablation, therapeutic delivery, radiosensitization, sonodynamic therapy, and enhancement of tumor-specific immune responses. Given the breadth of this burgeoning domain, this review places a spotlight on recent advancements in breast cancer care to exemplify the multifaceted role ofFUS technology for oncology indications—outlining physical principles ofFUS-mediated thermal and mechanical bioeffects, giving an overview of results from recent preclinical and clinical studies investigating FUS with and without adjunct therapeutics in primary or disseminated breast cancer settings, and offering perspectives on the future of the field.  \nKeywords  \nfocused ultrasound; breast cancer; metastasis; cancer immunotherapy; image-guided therapy;  \nHIFU; drug delivery  \nINTRODUCTION  \nBreast Cancer: Global Landscape and Critical Gaps  \nBreast cancer (BC) remains the most common cancer diagnosis and second-leading cause of cancer-related deaths in women worldwide. The morbidity and mortality associated with BC are frequently attributable to metastases (for instance, to lung, liver, bone, or lymph nodes), with brain metastases being among the most formidable (1) . In 2024, the National  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information.  \n[qkh9uu@virginia.edu](qkh9uu@virginia.edu), [nds3sa@virginia.edu](nds3sa@virginia.edu).  \nDISCLOSURE STATEMENT  \nThe authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nDemir and Sheybani Page 2  \nCancer Institute estimated 310,780 new breast cancer cases in the United States alone, with its prevalence on the rise. Among these women, those of African American descent are disproportionately affected by BC, with incidence continuing to rise compared with the White population (2) .  \nThe diagnosis and prognostication of BCs are rooted in the interlacing of traditional clinico-pathological variables (i.e., tumor size, grade, lymph node positivity, age) with immunohistological benchmarks for proliferation index (Ki67), hormone receptor status [i.e., expression of estrogen receptor (ER) and progesterone receptor (PR)], and human epidermal growth factor receptor (HER2) levels. A summary of BC subtypes is provided in Supplemental Table 1. Briefly, luminal A tumors are characterized by the expression of ER and/or PR, as well as the absence of HER2 and low Ki67 index. These tumors tend to be lower grade, which is associated with higher patient sur","cbCaih4zJLvkMHg2","https://ap.wps.com/l/cbCaih4zJLvkMHg2","pdf",1502915,33,"English","# Abstract\n# Keywords\n# Introduction\n## Breast Cancer: Global Landscape and Critical Gaps","[{\"question\":\"What is the core rationale for using focused ultrasound (FUS) in cancer treatment?\",\"answer\":\"FUS enables nonionizing, noninvasive intervention and can produce multiple bioeffects. These functions support tumor ablation, therapeutic delivery, radiosensitization, sonodynamic therapy, and immune response enhancement.\"},{\"question\":\"Which breast cancer–related areas does the review focus on?\",\"answer\":\"The review highlights recent advances in breast cancer care using FUS, summarizing physical principles and reporting outcomes from preclinical and clinical studies. It covers FUS used alone and in combination with adjunct therapeutics for primary and disseminated settings.\"},{\"question\":\"How do breast cancer subtypes influence treatment strategies discussed in the document?\",\"answer\":\"The document links subtypes to key biomarkers such as ER/PR and HER2, and to clinical variables like grade and proliferation index. It describes differing prognosis and therapeutic targeting needs, including hormone therapy for luminal tumors and HER2-targeted strategies for HER2+ disease, as well as challenges in triple-negative breast cancer.\"}]","Therapeutic Ultrasound for Multimodal Cancer Treatment - A Spotlight on Breast Cancer | PDF",1790184746,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7137085e16dd410908cf9d34c93bd51.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/163c8eee03887242812840b6a40fa609.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/676be946d18ec31ac976d926c2bd23bf.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f48bf8719199267f7cfbed3cb133e40f.webp",980,1268]